Month: February 2020

ROCHESTER, Mich., Feb. 18, 2020 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, has launched its first health technology solution from OptimizeRx Innovation Lab, aimed at increasing speed to therapy for patients by providing timely access to enrollment forms within the provider workflow, making it easier for patients to enroll in specialty drug support programs provided by hub services.Part of the OptimizeRx platform, the new hub-enrollment solution improves patient access to specialty medications in two ways: First, it alerts healthcare providers that the chosen drug must be filled at a specialty pharmacy – at the time that the provider is writing the script in the electronic health record (EHR). Second, the solution automatically surfaces...

Bestyrelsen for Investeringsforeningen Multi Manager Invest har i dag behandlet og godkendt foreningens årsrapport for 2019.Foreningen oplevede afkastmæssigt et godt år i 2019. Alle afdelinger leverede positive afkast, der var væsentligt højere end ledelsens forventninger primo året.Samtlige afdelingers afkast var højere end afdelingernes respektive benchmark. Ledelsen finder afkastudviklingen i foreningens afdelinger tilfredsstillende.For det kommende år skønner ledelsen moderat positive afkast for foreningens afdelinger. Afkastene i 2020 må forventes at blive markant lavere end de afkast, der blev opnået i 2019. Væsentlige afkastudsving i foreningens afdelinger må forventes, og negative afkast kan ikke udelukkes i 2020.Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted, tlf. 44 55 92 00.Med venlig...

SAN DIEGO, Feb. 18, 2020 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that Ron Rocca, CEO of Exagen, will present at the Cowen and Company 40th Annual Healthcare Conference on Monday, March 2, 2020 in Boston.  Mr. Rocca’s presentation will take place at 3:30 p.m. EST. A link to the live webcast of the presentation will be available online from the investor relations section of the Exagen website at https://investors.exagen.com/A replay of the webcast will be accessible on the Exagen investor relations website beginning approximately one hour following the completion of the event.About Exagen Inc.Exagen...

VANCOUVER, Colombie-Britannique, Feb. 18, 2020 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc. (« AgraFlora » ou la « Société ») (CSE : AGRA) (Frankfurt: PU31) (OTCPK : AGFAF) une société internationale de cannabis diversifiée et axée sur la croissance est heureuse d’annoncer que la filiale à part entière de la société, Farmako GmbH (« Farmako ») continue de se positionner comme un grossiste pharmaceutique compétitif en vue d’assurer un accès durable aux produits à base de cannabis médical pour les patients sur le marché allemand. Le 13 février 2020, Farmako a reçu une autorisation spéciale du Federal Institute for Drugs and Medical Devices (« BfArm ») pour la distribution de fleurs de cannabis médical, qui ont subi un traitement par irradiation (la « licence AMRadV »).La licence AMRadV est obligatoire en Allemagne pour...

LYON, France, February 18, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company recently showcased its Focal One high intensity focused ultrasound (HIFU) device at the 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, which was held February 9-11 in Washington, DC. This marks the first time that the symposium was held in the U.S. since FDA clearance of Focal One in June 2018.  “We are pleased to have been featured in this very prestigious and highly specialized symposium on focal imaging and therapy that attracts urology thought leaders from around the world,” said Marc Oczachowski, Chief Executive Officer of EDAP. “This annual gathering is the most important and referenced event for focal therapy in urology disorders,...

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, will present a corporate update at the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020 in New York City.A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at www.satsumarx.com. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.About Satsuma Pharmaceuticals and STS101Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device...

REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) — Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced results from an integrated efficacy analysis on the two pivotal Phase 3 clinical trials for FMX103 (minocycline, 1.5% foam) currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe papulopustular rosacea in adults. The new data have been presented at the 17th Annual South Beach Symposium in Dermatology held on February 6-9, 2020 in Miami, Florida.Foamix previously announced that the FDA has accepted the filing of a New Drug Application for FMX103 for the treatment of moderate...

DURHAM, N.C., Feb. 18, 2020 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, February 25, 2020 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2019, and to provide a business overview.To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1397800. A live audio webcast of the call will also be available on the Investors’ section of the Company’s website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately...